{"organizations": [], "uuid": "ad93c1daeb8dd5a4906e7073627b610fd89a4433", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180511.html", "section_title": "Archive News &amp; Video for Friday, 11 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-david-horn-solomon-resigns-as-ceo/brief-david-horn-solomon-resigns-as-ceo-of-akari-therapeutics-idUSFWN1SI0OW", "country": "US", "domain_rank": 408, "title": "BRIEF-David Horn Solomon Resigns As CEO Of Akari Therapeutics", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-11T20:50:00.000+03:00", "replies_count": 0, "uuid": "ad93c1daeb8dd5a4906e7073627b610fd89a4433"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-david-horn-solomon-resigns-as-ceo/brief-david-horn-solomon-resigns-as-ceo-of-akari-therapeutics-idUSFWN1SI0OW", "ord_in_thread": 0, "title": "BRIEF-David Horn Solomon Resigns As CEO Of Akari Therapeutics", "locations": [], "entities": {"persons": [{"name": "david horn solomon", "sentiment": "negative"}, {"name": "horn solomon", "sentiment": "none"}, {"name": "clive richardson", "sentiment": "none"}], "locations": [], "organizations": [{"name": "brief-david horn solomon resigns", "sentiment": "negative"}, {"name": "akari therapeutics plc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "akari therapeutics", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "solomon on co", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 11 (Reuters) - Akari Therapeutics PLC:\n* AKARI THERAPEUTICS SAYS ON MAY 8, DAVID HORN SOLOMON, RESIGNED AS CEO AND AS A MEMBER OF BOARD EFFECTIVE IMMEDIATELY - SEC FILING\n* AKARI THERAPEUTICS - ALSO EFFECTIVE ON MAY 8, BOARD APPOINTED CLIVE RICHARDSON TO SERVE AS INTERIM CEO\n* AKARI THERAPEUTICS PLC - HORN SOLOMON’S RESIGNATION FOLLOWS THE RESULTS OF AN INVESTIGATION CONDUCTED, WITH THE ASSISTANCE OF AN INDEPENDENT LAW FIRM\n* AKARI THERAPEUTICS PLC - INVESTIGATION REVEALED HORN SOLOMON INCURRED PERSONAL CHARGES ON CO’S CORPORATE CREDIT CARDS IN VIOLATION OF CO POLICY\n* AKARI THERAPEUTICS - CO DOES NOT CONSIDER AMOUNTS CHARGED BY HORN SOLOMON ON CO'S CORPORATE CREDIT CARDS TO BE MATERIAL TO CO'S OPERATIONS Source text ( bit.ly/2rzqNaS ) Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/", "https://bit.ly/2rzqNaS"], "published": "2018-05-11T20:50:00.000+03:00", "crawled": "2018-05-12T17:39:25.000+03:00", "highlightTitle": ""}